Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA)

Cuesta‐Herranz, Javier; Laguna, José Julio; Mielgo, R.; Pérez-Camo, I; Callejo, Ana Mariño; Begoña, Leire; Gomez, Mario; Madariaga, Begoña; Martinez, A.

doi:10.23822/eurannaci.1764-1489.104

Cited by 9 publications

(11 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…We also found statistically significant differences in how patients in all subgroups rated their quality M a n u s c r i p t a c c e p t e d f o r p u b l i c a t i o n of life after completing AIT. This finding is well in accordance with reports by other researchers [21].…”

Section: Discussionsupporting

confidence: 94%

Pre-treatment allergen-specific IgE analysis and outcomes of allergen immunotherapy

Berge

Bertilsson

Hultgren

et al. 2022

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

Section: Discussionsupporting

confidence: 94%

Pre-treatment allergen-specific IgE analysis and outcomes of allergen immunotherapy

Berge

Bertilsson

Hultgren

et al. 2022

Eur Ann Allergy Clin Immunol

View full text Add to dashboard Cite

“…Another study also stated that the administration of immunotherapy to allergic patients significantly improved their quality of life [ 48 ]. Recent studies also found that giving participants specific immunotherapy can improve their quality of life, which is followed by a decrease in the intensity of allergy recurrence found after the use of immunotherapy [ 49 ]. Immunotherapy has been shown to improve the quality of life of participants by reducing the intensity of allergy symptoms, improving physical condition, and also reducing dependence on drug consumption [ 10 , 42 , 48 , 49 ].…”

Section: Discussionmentioning

confidence: 99%

“…Other studies have also stated that the improvement in symptoms of CRA can be significantly improved with the use of specific immunotherapy [ 42 ]. The use of specific allergy immunotherapy has been shown to shorten the symptoms of CRA, which is usually 14 weeks, can be reduced to 3–4 weeks [ 49 ].…”

Section: Discussionmentioning

confidence: 99%

The role of house dust mite immunotherapy in Indonesian children with chronic rhinosinusitis allergy: A randomized control trial

Putera

Hikmah

Endaryanto

et al. 2021

Heliyon

View full text Add to dashboard Cite

Background Chronic rhinosinusitis allergy (CRA) is a disease that is commonly found in children and is mostly caused by allergy to house dust mites (HDM). The use of HDM immunotherapy can be considered in children with allergies. Objectives Analyzing the impact of mite immunotherapy on disease burden in Indonesian children with CRA. Methods A randomized control trial study was conducted to participants in 2 groups, namely the immunotherapy group (n = 25) and the non-immunotherapy group (n = 25). Participants were given HDM immunotherapy for 14 weeks, which was given once per week. Participants during therapy were evaluated for rhinosinusitis symptoms and measured their immunity status (specific IgE), sleep quality (SDSC), quality of life (SN5), and family coping (F-COPES) pre-post therapy. Statistical analysis used in this study included paired t-test, Wilcoxon test, independent t-test, or Mann Whitney test with p < 0.05. Results The value of specific IgE in the immunotherapy group was 4.12 ± 7.75 kU/l (pre-test) and 1.52 ± 2.42 kU/l (post-test; p < 0.001), while in the non-immunotherapy group was 1.47 ± 3.28 kU/l (pre-test) and 1.18 ± 2.81 kU/l (post-test; p = 0.317). The SDSC value in the immunotherapy group was 42.16 ± 2.75 (pre-test) and 30.32 ± 3.22 (post-test; p < 0.001), while in the non-immunotherapy group was 41.92 ± 2.75 (pre-test) and 41.84 ± 2.87 (post-test; p = 0.987). The F-COPES value in the immunotherapy group was 101.56 ± 5.78 (pre-test) and 105.20 ± 4.31 (post-test; p = 0.015), while in the non-immunotherapy group was 100.36 ± 9.63 (pre-test) and 99.96 ± 9.98 (post-test; p = 0.224). The SN-5 value in the immunotherapy group was 30.04 ± 2.78 (pre-test) and 11.00 ± 2.33 (post-test; p < 0.001), while in the non-immunotherapy group was 30.04 ± 2.78 (pre-test) and 30.04 ± 2.78 (post-test; p = 0.767). There was a significant comparison between the immunotherapy group and the non-immunotherapy group on the specific IgE ( p = 0.013), SDSC ( p < 0.001), and SN-5 ( p < 0.001) values. Meanwhile, there was no significant difference in the F-COPES value ( p = 0.129). Conclusions The administration of HDM immunotherapy can improve the participant's immunity, quality of life, and sleep disorder.

show abstract

“…In this article, an improvement in disease-related quality of life was observed one pollen season after treatment initiation, similar to findings in different clinical trials 14,18,19 and observational studies. 20 These results show that both perennial and bi-weekly pre-co-seasonal schedules, both reaching almost the same cumulative dose at pollen season are effective, thus, stressing the importance of the cumulative dose a patient receives before the pollen season irrespective of treatment schedule.…”

Section: Discussionmentioning

confidence: 67%

Evaluation of a pre-co-seasonal and a perennial schedule of a single multiallergen depigmented-polymerized subcutaneous immunotherapy in paediatric patients.

Martinez

Torres

Molina

et al. 2021

aei

View full text Add to dashboard Cite

Aim: Compare a pre-co-seasonal with a perennial schedule using an undiluted mixture of a depigmented-polymerized grass/Olea europaea immunotherapy (2,000 DPP/mL) in pediatric patients with rhinitis/rhinoconjunctivitis with or without controlled asthma.Material and Methods: Primary objective was to determine the non-superiority of a perennial compared to a pre-co-seasonal schedule by means of Paediatric/Adolescent Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ/AdolRQLQ). Secondary objectives were Paediatric Asthma/Caregiver´s Quality of Life Questionnaire (PAQLQ/PACQLQ) Asthma Control Test (ACT), Visual Analogue Scale global assessment of allergic disease (VAS), use of resources and immunological response. All variables were compared during the pollen season (April-June) without (2015) and with (2016) immunotherapy.Results: Forty patients were included in the study of which 29 patients were assigned to the perennial and 11 to the pre-co-seasonal schedule. During 2016 pollen season a significant improvement in the PRQLQ/AdolRQLQ, PAQLQ/AdolAQLQ, ACT and VAS score were observed both in perennial and pre-co-seasonal schedule group. No significant differences were seen between treatment schedules for PRQLQ/AdolRQLQ, PAQLQ/AdolAQLQ and ACT scores comparing both pollen seasons. A significant increase in sIgG4 and reduction in the number of rescue medications used and number of patients who needed visit to any specialist was observed in both treatment schedules during 2016 pollen season. No relevant differences were found in the safety profile of any treatment schedule.Discussion: Treatment with undiluted mixture of a depigmented-polymerized Grass/Olea europaea allergen immunotherapy has proven to be effective both using a perennial and a pre-co-seasonal schedule and therefore suitable for polyallergic patients.

show abstract

Quality of life improvement with allergen immunotherapy treatment in patients with rhinoconjunctivitis in real life conditions. Results of an observational prospective study (ÍCARA)

Cited by 9 publications

References 35 publications

Pre-treatment allergen-specific IgE analysis and outcomes of allergen immunotherapy

Pre-treatment allergen-specific IgE analysis and outcomes of allergen immunotherapy

The role of house dust mite immunotherapy in Indonesian children with chronic rhinosinusitis allergy: A randomized control trial

Evaluation of a pre-co-seasonal and a perennial schedule of a single multiallergen depigmented-polymerized subcutaneous immunotherapy in paediatric patients.

Contact Info

Product

Resources

About